Journal Watch · Pharmacology & Therapeutics · 2026
The regulatory and therapeutic potential of transposable elements in cancer and inflammatory diseases.
In this review, we summarize the classification and regulatory functions of TEs, discuss their roles in immune regulation, inflammation and cancer, and examine emerging therapeutic strategies targeting TE-associated pathways in cancer and inflammatory diseases.
TL;DR
In this review, we summarize the classification and regulatory functions of TEs, discuss their roles in immune regulation, inflammation and cancer, and examine emerging therapeutic strategies targeting TE-associated pathways in cancer and inflammatory diseases.
Key findings
- In this review, we summarize the classification and regulatory functions of TEs, discuss their roles in immune regulation, inflammation and cancer, and examine emerging therapeutic strategies targeting TE-associated pathways in cancer and inflammatory diseases.
What they did
Emerging evidence demonstrates that TEs contribute to immune cell differentiation, enhancer landscape formation, interferon signaling, and inflammatory responses through diverse mechanisms, including the generation of regulatory non-coding RNAs, alternative splicing events, and TE-derived peptides presented by major histocompatibility complex molecules. In addition to their roles in cancer biology, dysregulated TE activities have also been implicated in aging-associated and inflammatory disorders.
Full abstract (original)
Background: Transposable elements (TEs), commonly known as "jumping genes," constitute nearly half of the human genome and are increasingly recognized as important regulators of gene expression, chromatin organization, and immune signaling. Although most TEs are epigenetically silenced under physiological conditions, aging, chronic inflammation, and cancer can induce TE reactivation, leading to genomic instability, innate immune activation, and transcriptional reprogramming.
What they did: Emerging evidence demonstrates that TEs contribute to immune cell differentiation, enhancer landscape formation, interferon signaling, and inflammatory responses through diverse mechanisms, including the generation of regulatory non-coding RNAs, alternative splicing events, and TE-derived peptides presented by major histocompatibility complex molecules. In addition to their roles in cancer biology, dysregulated TE activities have also been implicated in aging-associated and inflammatory disorders.
Results & conclusions: In this review, we summarize the classification and regulatory functions of TEs, discuss their roles in immune regulation, inflammation and cancer, and examine emerging therapeutic strategies targeting TE-associated pathways in cancer and inflammatory diseases.
Abstract © the authors / Pharmacology & Therapeutics (2026). Reproduced here for discussion and indexing, with attribution. Read the original at https://doi.org/10.1016/j.pharmthera.2026.109128 · PubMed 42790755.
Why it matters for pharma & biotech
- Relevant to Pharmacology & Drug Discovery teams tracking Pharmacology & Therapeutics for new targets, mechanisms and biomarkers.
- As earlier-stage work, its near-term value is target validation and assay design rather than clinical decisions.
- For searchers: the full abstract is reproduced below, so you can judge relevance before opening the publisher page.
Limitations & what to check in the full text
- This brief is based on the published abstract only. Effect sizes, subgroup results and safety detail in the full text may qualify the headline findings.
- As a review, this paper synthesises prior studies rather than reporting new experimental data; weight it accordingly.
- The abstract reports its conclusions qualitatively, without headline effect sizes — read the full text before citing a magnitude.
Frequently asked questions
What did this Pharmacology & Therapeutics study find?
In this review, we summarize the classification and regulatory functions of TEs, discuss their roles in immune regulation, inflammation and cancer, and examine emerging therapeutic strategies targeting TE-associated pathways in cancer and inflammatory diseases.
What type of study is this?
It is a review / perspective, published in Pharmacology & Therapeutics in 2026. Emerging evidence demonstrates that TEs contribute to immune cell differentiation, enhancer landscape formation, interferon signaling, and inflammatory responses through diverse mechanisms, including the generation of regulatory non-coding RNAs, alternative splicing events, and TE-derived peptides presented by major histocompatibility complex molecules.
Where can I read the original paper?
The original is at the publisher via DOI 10.1016/j.pharmthera.2026.109128. PubMed ID: 42790755. BioStudioAI reproduces the abstract for discussion and links to the source.
This brief: BioStudioAI Journal Watch, 29 October 2026. https://biostudioai.com/blog/papers/the-regulatory-and-therapeutic-potential-of-transposable-elements-in-can-109128/
Reading papers is step one. Analysing the data is the work.
BioStudioAI turns raw lab files into QC'd results, statistics, figures, reports and slides — hosted on your servers, every number computed, nothing typed.
Open BioStudioAI More guides